Novartis’ Kymriah fails to hit primary survival endpoint in late-stage trial
Phase III study was investigating treatment for B-cell non-Hodgkin lymphoma
Read More
Tag: CAR-T therapy
Janssen’s myeloma CAR T therapy cilta-cel demonstrates ‘sustained efficacy’
Updated study results showed an overall response rate of 98% with a longer-term follow-up at a median of 18 months
Read More
Janssen seeks EU approval for first CAR-T therapy cilta-cel
Cilta-cel is an investigational CAR-T cell therapy for the treatment of relapsed/refractory multiple myeloma
Read More
BMS to invest in new cell therapy manufacturing site in Europe
Construction on Leiden, Netherlands site anticipated to begin later this year
Read More
FDA green light for BMS, bluebird bio’s CAR-T therapy Abecma in multiple myeloma
CAR-T therapy cleared for use in adults with relapsed or refractory multiple myeloma
Read More
Tecartus wins NICE recommendation for mantle cell lymphoma
CAR-T therapy receives NICE backing within weeks of EMA authorisation
Read More
Kite’s CAR T therapy Tecartus authorised in EU for MCL
CHMP backed the CAR T cell therapy for the treatment of mantle cell lymphoma back in October
Read More
Kite’s CAR T therapy Yescarta shows potential in new indication
ZUMA-12 phase II study is evaluating therapy as a first-line treatment for high-risk large B-cell lymphoma
Read More
Novartis’ CAR-T therapy Kymriah hits endpoint in follicular lymphoma trial
Company expect to file regulatory submissions in 2021
Read More
Oxford Biomedica and Beam Therapeutics sign CAR-T deal
Agreement will utilise Oxford Biomedica’s LentiVector platform
Read More
NHS to fast-track ‘game changing’ cancer drugs
The revolutionary treatments can be used against a wide range of cancers.
Read More
EMA grants PRIME designation to Janssen’s investigational CAR-T therapy
Based on a study that found 88% overall response rate in advanced relapsed or refractory multiple myeloma.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
